Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxygen and Acetazolamide for Opioid-Associated Sleep Disordered Breathing
NCT05589753Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- May 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in sleep apnea and sleep disordered breathing (SDB) comparing Hyperoxia with Acetazolamide (ACZ) (2 arms). Primary endpoints: Apneic threshold, Cerebrovascular responsiveness to carbon-dioxide at 7 days and 2 more. Started May 2019; status: recruiting.
02
Drugs
acetazolamideoxygen
03
Conditions
sleep apneasleep disordered breathing (SDB)
Beyond the preview
Go deeper on NCT05589753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05589753.